Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd

I'm busy working on my blog posts. Watch this space!

Please reload

Follow Us

February 12, 2019

LIfT BioSciences comes first for the UK, and second place in the whole of Europe out of more than 200 companies that qualified for entry into the European Institute for Innovation & Technology (EIT) Accelerator programme across multiple health related industries.

Dr Van...

February 12, 2019

Alex Blyth, CEO of LIfT BioSciences, delivered the closing presentation for The 25th Prostate Cancer Foundation Retreat in Carlsbad, USA to an audience of the world's leading experts and authorities on Prostate Cancer.

The presentation solidified Innate Cell Therapies...

November 6, 2018

LIfT BioSciences has received a significant investment in its mission to develop the first curative and affordable cell therapy for all solid tumours. Leading biotech investors include the co-founder of Abcam plc, Jonathan Milner, now an important cornerstone investor...

May 1, 2018

LIfT BioSciences has been awarded Best Rising Start-Up at BioVaria 2018 by the experienced panel of judges, comprised of major Pharma Companies, Venture Capital Firms & NGOs.

Over 250 innovative minds gathered in Munich on April 23-24 for the 11th BioVaria to discuss em...

March 23, 2018

LIfT BioSciences has successfully raised £300K in seed funding to help complete their cutting-edge laboratory work towards developing the world's first cell bank of lab cultured cancer-killing leukocytes later this year. The funding follows on from the initial round of...

November 27, 2017

Read full article here

- Note: An inaccuracy in this article is that LIfT will use survivor donor cells. We will be recruiting donors with a range of backgrounds, including specifically healthy volunteers who have no history of cancer personally or in the their family.

November 25, 2017

Early-stage research has shown that cancer cells from a well-known human cancer cell line (HeLa cells) can be killed by human neutrophils (a type of innate immune cell) that have been produced in a laboratory (rather than in the body). The breakthrough early-stage rese...

May 2, 2017

The European Medicines Agency (EMA) have classified LIfT's enhanced allogeneic granulocyte therapy as a somatic cell therapy MP, a type of Advanced Therapeutic Medicinal Product (ATMP).

LIfT BioSciences CEO, Alex Blyth, commented that "ATMP status (rather than being a m...

April 19, 2017

Scientists are searching for people with a rare genetic mutation that can supercharge immune systems

Read Article

Please note: there are inferences made in this article that are not the views expressed by LIfT BioSciences Ltd

Please reload

  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square
Please reload

Recent Posts
Search By Tags
Archive
Please reload

LATEST NEWS

Note: This website contains certain statements that are not historical facts and may be forward-looking statements, please see our legal notice. Links provided from this website to other web pages over which the company has no control, are so provided for convenience only and as such, the company neither endorses nor makes any representations as to the accuracy or any other aspect of the information contained in such other web pages.